Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Andrea Barnes Andrea Barnes is a writer covering large cleaning appliances.